May 4-6, 2021, 32nd Annual Cancer Progress Conference, Online
May 11, 2021, Redeye Investor Online Forum, Online
May 17-19, 2021, Bio€quity Europe, Online
May 26-27, 2021, BioStock Life Science Spring Summit, Online
Pareto Securities - interview with CEO Martin Welschof, March 3, 2021 > Link
Healthcare Direct, CEO interview, February 25, 2021 > Link
Annual General Meeting, April 29, 2021 > Link
BioInvent’s strategy is to leverage its expertise in immunology, cancer biology and antibody biology to develop cancer immunotherapies to improve the quality of life for cancer patients. This is accomplished through collaborations with pharmaceutical companies, academic research groups, networks of clinical specialists and research foundations. The goal is to create value for the Company’s shareholders based on successful drug development and subsequent revenue streams from existing and future commercial partners.
Our tools for successful drug development
In an automated process, we select optimal antibodies for new drug candidates from our own antibody library – one of the largest in the world.
Our unique and patented screening-platform has the advantage of simultaneously identifying disease-associated targets and antibodies that bind to them.